Secretomics identifies follistatin as a predictive biomarker for response to treatment with tyrosine kinase inhibitors in synovial sarcoma

Sarcoma is a rare malignancy with an aggressive clinical course. Tyrosine kinase inhibitors (TKIs) have emerged as effective drugs in targeted therapy for malignancies; in particular, pazopanib was recently approved for the treatment of sarcoma. However, as only a limited proportion of patients exhi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of Electrophoresis 2017, Vol.61(1), pp.1-7
Hauptverfasser:	Qiao, Zhiwei, Kito, Fusako, Takai, Yoko, Oyama, Rieko, Kondo, Tadashi
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers follistatin Gene expression Genes Immunoassay Inhibitors Kinases Patients predictive biomarker Sarcoma secretomics synovial sarcoma Tyrosine tyrosine kinase inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!